Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
/ analysis
Biomarkers, Tumor
/ analysis
Breast Neoplasms
/ chemistry
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Carcinoma, Intraductal, Noninfiltrating
/ chemistry
Female
Humans
Immunophenotyping
Lymphocytes, Tumor-Infiltrating
/ immunology
Middle Aged
Phenotype
Prognosis
Receptor, ErbB-2
/ analysis
Retrospective Studies
Triple Negative Breast Neoplasms
/ chemistry
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
08
03
2019
accepted:
03
07
2019
revised:
03
07
2019
pubmed:
4
8
2019
medline:
26
1
2021
entrez:
4
8
2019
Statut:
ppublish
Résumé
Ductal carcinoma in situ of the breast includes several subtypes with a divergent biological behavior. Data regarding the composition of ductal carcinoma in situ-associated immune cells and their potential role in progression is limited. We studied ductal carcinoma in situ-associated immune response by characterizing immune cell subsets according to ductal carcinoma in situ subtypes. Ductal carcinoma in situ-associated tumor infiltrating lymphocyte (TIL) density was evaluated based on hematoxylin and eosin (H&E)-stained sections from 473 patients. Cases were subtyped based on ER, PR, and HER2. Patients were categorized as TIL-high or low. Ductal carcinoma in situ-associated immune cells of TIL-high cases were immunostained on whole slides with CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 and SP263). In total, 131/473 patients (28.0%) were considered as TIL-high. The percentage of TIL-high cases was significantly higher in HER2+ and triple-negative ductal carcinoma in situ (P < 0.0001). Overall, no statistical difference in immune cell composition according to subtypes was found. However, individual subtype comparison showed that ER+ HER2+ cases had a significantly higher proportion of CD8+ T cells compared with triple-negative cases (P = 0.047). In TIL-high cases, PD-L1-SP142 expression on tumor cells was associated with subtype (P = 0.037); the lowest number of positive cases was observed in the HER2+ subtype (independent of ER). However, in TIL-high ductal carcinoma in situ, PD-L1 expression by both clones was limited. In conclusion, high numbers of TILs are predominantly observed in HER+ and triple negative ductal carcinoma in situ. The ER+ HER2+ subtype seems to attract a higher proportion of CD8+ T cells compared with the triple negative subtype. Among TIL-high cases, the HER2+ subgroup had the lowest PD-L1-SP142 expression on tumor cells. This suggests a more pronounced antitumor immunity in HER2+ ductal carcinoma in situ, which could play a role in its biological behavior.
Identifiants
pubmed: 31375764
doi: 10.1038/s41379-019-0331-8
pii: S0893-3952(22)00924-3
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
196-205Références
Perou CM, Sùrlie T, Eisen MB, Rijn MVanDe, Jeffrey SS, Rees CA, et al. Molecular portraits breast cancer. Nature. 2000;533:747–52.
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol. 2013;24:2206–23.
pubmed: 23917950
pmcid: 23917950
Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228–41.
pubmed: 26667975
Kotoula V, Chatzopoulos K, Lakis S, Alexopoulou Z, Timotheadou E, Zagouri F, et al. Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget. 2016;7:5074–87.
pubmed: 26506242
Aaltomaa S, Lipponen P, Eskelinen M, Kosma V, Marin S, Alhava E, et al. Lymphocyte Infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. 1992;28:859–64.
Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JBAG, van Vugt MATM, de Vries EGE, et al. Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer. J Natl Cancer Inst. 2017;109:djw192.
Mao Y, Qu Q, Chen X, Huang O, Wu J, Shen K. The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0152500.
pubmed: 27073890
pmcid: 4830515
Kaur H, Mao S, Shah S, Gorski DH, Krawetz SA, Sloane BF, et al. Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ. Expert Rev Mol Diagn. 2013;13:151–65.
pubmed: 23477556
pmcid: 3804339
Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57:171–92.
pubmed: 20500230
Barnes NLP, Ooi JL, Yarnold JR, Bundred NJ. Ductal carcinoma in situ of the breast How does DCIS develop? BMJ. 2012;344:e797.
pubmed: 22378935
Bleyer A, Welch G. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998–2005.
pubmed: 23171096
Virnig BA, Wang S-Y, Shamilyan T, Kane RL, Tuttle TM. Ductal carcinoma in situ: risk factors and impact of screening. J Natl Cancer Inst Monogr. 2010;2010:113–6.
pubmed: 20956813
pmcid: 5161075
Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy. Cancer. 2005;103:1778–84.
pubmed: 15770688
Page D, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76:1197–200.
pubmed: 8630897
Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103:2481–4.
pubmed: 15884091
Chivukula M, Domfeh A, Carter G, Tseng G, Dabbs DJ. Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications. Appl Immunohistochem Mol Morphol. 2009;17:495–9.
pubmed: 19407654
Wasserman JK, Parra-Herran C. Regressive change in high-grade ductal carcinoma in situ of the breast: histopathologic spectrum and biologic importance. Am J Clin Pathol. 2015;144:503–10.
pubmed: 26276781
Morita M, Yamaguchi R, Tanaka M, Tse GM, Yamaguchi M, Kanomata N, et al. CD8+ tumor-infiltrating lymphocytes contribute to spontaneous “healing” in HER2-positive ductal carcinoma in situ. Cancer Med. 2016;5:1–12.
Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Investig. 2015;125:3335–7.
pubmed: 26325031
Vonderheide RH, Domchek SM, Clark AS. Immunotherapy for breast cancer: what are we missing? Clin Cancer Res. 2017;23:2640–6. https://doi.org/10.1158/1078-0432.CCR-16-2569 .
doi: 10.1158/1078-0432.CCR-16-2569
pubmed: 28572258
pmcid: 5480967
Hammerl D, Smid M, Timmermans A, Sleijfer S, Martens JW, Debets R. Breast cancer genomics and immuno-oncological markers to guide immune therapies. Semin Cancer Biol. 2018;52:178–88.
pubmed: 29104025
Gorringe KL, Fox SB. Ductal carcinoma in situ biology, biomarkers, and diagnosis. Front Oncol. 2017;7:248.
pubmed: 29109942
pmcid: 5660056
Zhou W, Jirström K, Amini R-M, Fjällskog M-L, Sollie T, Lindman H, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. BMC Cancer. 2012;512:1–9.
Clark S, Warwick J, Carpenter R, Bowen R, Duffy S, Jones J. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer. 2010;104:120–7.
pubmed: 21139586
pmcid: 3039794
Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, et al. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol. 2017;28:321–8.
pubmed: 28426105
Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. 2014;2014:469251.
pubmed: 24955090
pmcid: 4058253
Doebar SC, van den Broek EC, Koppert LB, Jager A, Baaijens MHA, Obdeijn IMAM. et al. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. Breast Cancer Res Treat. 2016;158:179–87.
pubmed: 27318854
pmcid: 4937080
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4–13.
pubmed: 19574486
pmcid: 2705275
Tot T. Early (<10 mm) HER2-positive invasive breast carcinomas are associated with extensive diffuse high-grade DCIS: implications for preoperative mapping, extent of surgical intervention, and disease-free survival. Ann Surg Oncol. 2015;22:2532–9.
pubmed: 25582746
Liao N, Zhang G-C, Liu Y-H, Li X-R, Yao M, Xu F-P, et al. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. Pathol Pr. 2010;207:1–7.
Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer. 2016;24:1–13.
Agahozo MC, Hammerl D, Debets R, Kok M, van Deurzen CHM. Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes? Mod Pathol. 2018;31:1012–25.
pubmed: 29463884
Lee AHS, Happerfield LC, Bobrow LG, Millis RR. Angiogenesis and inflammation in ductal carcinomain situ of the breast. J Pathol. 1997;181:200–6.
pubmed: 9120726
Hendry S, Pang J-MB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG, et al. Relationship of the breast ductal carcinoma in situ immune microenvironment with clinico-pathological and genetic features. Clin Cancer Res. 2017;23:5210–7.
pubmed: 28611201
Beguinot M, Dauplat M-M, Kwiatkowski F, Lebouedec G, Tixier L, Pomel C, et al. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. BMC Cancer. 2018;18:129.
pubmed: 29394917
pmcid: 5797400
Campbell MJ, Baehner F, O’Meara T, Ojukwu E, Han B, Mukhtar R, et al. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2017;161:17–28.
pubmed: 27785654
Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, et al. The ratio of CD8 C /FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. Oncoimmunology. 2016;5:2162–402x.
Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC, Diez-Rodriguez M, et al. Prognostic significance of tumour infiltrating B-lymphocytes in breast ductal carcinoma in situ. Histopathology. 2017;71:258–68.
pubmed: 28326600
Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, et al. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016;29:249–58.
pubmed: 26769139
pmcid: 5484584
FEDERA. Human tissue and medical research: code of conduct for responsible use (2011). Rotterdam 2011.
Toss MS, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida PC, et al. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Mod Pathol. 2018;31:1226–36.
pubmed: 29559742
Dutch Institute for Clinical Auditing. Factsheet Indicatoren NABON Breast Cancer Audit (NBCA) 2017. Leiden. 2017.
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.
pubmed: 24101045
Abba MC, Gong T, Lu Y, Lee J, Zhong Y, Lacunza E, et al. A molecular portrait of high-grade ductal carcinoma in situ. Cancer Res Tumor Stem Cell Biol. 2016;18:3980–90.
Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 2015;17:124.
pubmed: 26341640
pmcid: 4560879
Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, et al. The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res. 2009;29:2445–51.
pubmed: 19596912
Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109:2705–13.
pubmed: 24129232
pmcid: 3833219
Gaule P, Smithy JW, Toki M, Rehman J, Patell-Socha F, Cougot D, et al. A quantitative comparison of antibodies to programmed cell death 1 Ligand 1. JAMA Oncol. 2017;3:256.
pubmed: 27541827
pmcid: 5491359